Skip to main content
Year archive

argenx SE — 2016 filings

All 24 regulatory filings released by argenx SE (1AE) in 2016, sourced directly from the official regulator.

24 Filings
2016 Period
2016 filings (24)
Filing Released Lang
argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine
Regulatory Filings
2016-12-29 English
argenx to provide updates on ARGX-113 and ARGX-110 during American Society of Hematology Annual Meeting
Regulatory Filings
2016-12-02 English
argenx to Present at Upcoming Investor Conferences
Investor Presentation
2016-11-08 English
argenx Reports Third Quarter 2016 Financial Results and Provides Business Update
Earnings Release 9M 2016
2016-10-27 English
Frost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPLE Antibody(TM)
Regulatory Filings
2016-10-05 English
Interim / Quarterly Report 2016
Interim / Quarterly Report H1 2016
2016-09-20 English
argenx to host inaugural R&D day and webcast on September 22, 2016
Investor Presentation
2016-09-15 English
argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results
Interim / Quarterly Report H1 2016
2016-08-26 English
argenx to Present at Wedbush PacGrow Healthcare Conference
Report Publication Announcement
2016-08-10 English
argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers
Earnings Release FY 2016
2016-06-30 English
argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111
Regulatory Filings
2016-06-03 English
argenx successfully closes €30 million private placement
Capital/Financing Update
2016-06-03 English
argenx announces private placement of 2,703,000 new shares for an aggregate amount of €30 million with institutional investors
Share Issue/Capital Change
2016-06-01 English
argenx Reports First Quarter 2016 Financial Results and Provides Business Update
Interim / Quarterly Report Q1 2016
2016-05-11 English
argenx announces results of Annual General Meeting 2016
AGM Information
2016-04-29 English
argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology
Regulatory Filings
2016-04-21 English
argenx announces Annual General Meeting of Shareholders 28 April 2016
AGM Information
2016-03-17 English
Annual Report 2015
Annual Report FY 2015
2016-03-16 English
argenx reports fourth quarter business update and full year 2015 financial results
Earnings Release FY 2015
2016-03-11 English
argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2015 Financial Results on 11 March 2016
Report Publication Announcement
2016-03-03 English
argenx: Home Member State Selection
Regulatory Filings
2016-02-26 English
argenx opens clinical trial sites in South Korea for ARGX-111 program
Regulatory Filings
2016-02-18 English
argenx to present at the LEERINK Partners 5th Annual Global Healthcare Conference
Investor Presentation
2016-02-05 English
argenx successfully closes transaction with US funds advised by subsidiaries of Federated Investors
Capital/Financing Update
2016-01-25 English